Namodenoson
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00790218)
Timeline
Indications
Mechanism of action
- Adenosine A3 receptorAGONIST
ADORA3 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O- Mol. weight
- 544.74 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL431733 ↗
Also known as
- cf102
- cf102
- cf102
- cf 102
- cf 102
- cf-102
- cf-102
- cf-102
- chloro-ib-meca
- ci-ib-meca
- ci-ib-meca
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06387342 | Phase 2 | Dec 15, 2024 | Can-Fite BioPharma, Tel Aviv University |
| NCT05201404 | Phase 3 | Jan 31, 2023 | BioStrategics Consulting Ltd, Can-Fite BioPharma |
| NCT04697810 | Phase 2 | Aug 15, 2021 | BioStrategics Consulting Ltd, Can-Fite BioPharma |
| NCT02927314 | Phase 2 | Feb 1, 2017 | Can-Fite BioPharma |
| NCT02128958 | Phase 2 | Sep 1, 2014 | Can-Fite BioPharma |
| NCT00790673 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2009 | Can-Fite BioPharma |
| NCT00790218 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2009 | Can-Fite BioPharma, Tel Aviv University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Can-Fite BioPharma | For profit | 7 | 7 | 2 | 2009 |
| BioStrategics Consulting Ltd | For profit | 2 | 0 | 2 | 2021 |
| Tel Aviv University | Academic/Hospital | 2 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1